
HHS announces interim enforcement discretion policy for six peptides (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500), providing conditional access while the 503A Bulks List rulemaking proceeds.
60-Second Clinical Brief
Research · November 22, 2026HHS announces interim enforcement discretion policy for six peptides (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500), providing conditional access while the 503A Bulks List rulemaking proceeds.
On October 28, 2026, the U.S. Department of Health and Human Services announced an interim enforcement discretion policy under which it does not intend to take action against 503A compounders that use six peptides -- BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 -- while the 503A Bulks List is finalized through rulemaking. The policy was published in the Federal Register on October 30, 2026 (91 FR 68526, Docket No. HHS-OASH-2026-0496). This is the most significant peptide compounding policy development of 2026. It comes over six months after the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted in July 2026 to recommend adding these six peptides to the 503A Bulks List, and follows the April 2026 removal of 12 peptides from the Category 2 do not compound list. The HHS interim policy bridges the gap between the PCAC's recommendations and the actual rulemaking that will finalize the 503A Bulks List, potentially taking years.

The HHS interim enforcement discretion policy creates a 503A Interim Access List of six peptide bulk drug substances listed in Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. These six peptides were previously classified as Category 2 bulk drug substances -- meaning the FDA flagged them as raising significant safety risks or having insufficient evidence of clinical need. The Category 2 designation, in effect from September 2023 until April 22, 2026, effectively blocked 503A compounding using these peptides. The HHS policy does not add these peptides to the 503A Bulks List. Instead, it exercises enforcement discretion: HHS states it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding drug products using these peptides, provided all ten conditions are met.
For patients: if you are currently using or considering one of these six peptides from a compounding pharmacy, the HHS policy means your compound may be covered under federal enforcement discretion, provided the pharmacy is meeting all 10 conditions. Ask your pharmacy: compounded products must have labeling that states "This is a compounded drug product. Not for resale." The bulk substance must come from an FDA-registered facility with valid COA documentation. Multi-peptide stacks are NOT covered under this enforcement discretion. For compounding pharmacies: the policy provides a regulatory framework for operating during the interim period, but documentation, COA records, single-API formulations, and proper labeling are critical. The policy does not add peptides to the 503A Bulks List, is not FDA approval, and HHS may revisit if safety signals arise. For the peptide ecosystem: this is the latest step in a three-stage regulatory sequence that began in 2026 and will continue through 2026-2030, showing gradual movement toward stabilizing access while maintaining quality safeguards.
The HHS interim enforcement discretion policy is the most important peptide regulatory development of Q4 2026, and it matters for anyone involved with or following peptide therapy. Here is what you need to take away: The policy works because it is conditional, not categorical. HHS is not saying these peptides are now "legal" or "approved." This is a significant difference, and anyone operating under the assumption that the policy is a free pass is misunderstanding the regulatory landscape. The single-API condition is the most operationally significant constraint. For compounding pharmacies, this means no more combo formulations under the guise of this policy. This will frustrate some practitioners and patients, but it is the clearest line the policy draws. The COA requirement is the quality safeguard that matters most. The requirement that bulk substances come from FDA-registered facilities with valid Certificates of Analysis covering identity, purity, potency, and contaminant screening is the policy's strongest patient-protection feature. If your compounding pharmacy cannot produce COAs that meet this standard, the enforcement discretion does not apply. This is not the end of the story -- it is the middle. The PCAC vote was July 2026. The HHS policy is October 2026. The final rule could be 2027 at the earliest, more likely 2028-2030. Anyone watching this space needs a long-term view. Ask your pharmacy these three questions: "Are your bulk peptide substances sourced from FDA-registered facilities with current COAs that cover identity, purity, potency, and contaminants?" "Does each compounded product contain only one of the six Appendix A peptides, or are they combined?" "Is the labeling on my compounded product required to state 'This is a compounded drug product. Not for resale'?" These questions cut through the regulatory noise and get to the practical conditions that determine whether your peptide compound is covered under the HHS policy.
Sources: (1) Federal Register Notice "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," 91 FR 68526, published October 30, 2026. Docket No. HHS-OASH-2026-0496. (2) HHS Policy Document with Appendix A (list of six peptides) and Appendix B (peptide identities and justifications). (3) PCAC July 2026 Meeting: Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026, voting on six peptides for 503A Bulks List eligibility. (4) Legal500 Analysis: Buchanan Ingersoll & Rooney, "FDA Submits Interim Peptide Compounding Policy For White House Review," October 22, 2026. (5) HK Law Analysis: "HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides," November 2026. (6) Venable Analysis: "In-Depth Analysis: HHS Announces Interim Enforcement Discretion for Section 503A Compounding," November 2026. (7) McDermott Law Analysis: "Peptides first, paperwork later: HHS clears six for compounding ahead of Bulks List rulemaking," October 28, 2026. (8) BIPC Compounding Guide: "What Compounding Pharmacies Need to Know About the HHS Interim Enforcement Discretion Policy for Six Peptides," October 2026. (9) JAMA Viewpoint: Samantaroy S, Xu I, Lurie P. "Peptides, FDA's Pharmacy Compounding Advisory Committee, and the Future of FDA Drug Approval." JAMA. 2026 Oct 26. doi: 10.1001/jama.2026.19125. (10) Am J Nurs: Roush K. "FDA Advisory Committee Recommends Previously Banned Peptides for Compounding." Am J Nurs. 2026 Nov 1;126(11):13-14. doi: 10.1097/AJN.0000000000000401a.
Evidence Grade: B
Rationale: This article is based on officially published primary sources: the Federal Register notice (91 FR 68526), the HHS policy document with Appendices A and B, FDA PCAC meeting records, and multiple independent legal/regulatory analyses from reputable firms. The factual claims about the six peptides, the 10 conditions for enforcement discretion, the covered routes/dosage forms, and the policy's effective date are all verified against these sources. The Evidence Grade of B reflects that the article relies on authenticated government documents and on-the-record legal analyses, with no fabricated data or unattributed claims. The grade could be upgraded to A if the full HHS Appendix B PDF (with detailed peptide identities and justifications) is independently verified, or downgraded if new safety signals cause HHS to revise the policy.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, treatment recommendations, or regulatory guidance. Compounded drugs are not FDA-approved and may pose risks to patients. Always consult with a licensed healthcare professional before starting, stopping, or modifying any medication or peptide therapy. The regulatory information provided here is based on publicly available government documents and legal analyses as of the publication date; regulatory policies may change. HHS may revisit the interim enforcement discretion policy at any time based on safety signals or product quality issues. State pharmacy and medical board requirements may impose additional restrictions. Neither the author nor Oria makes any representation about the safety, efficacy, or legality of any specific peptide compound or compounding practice.

2026 research reveals KPV suppresses adipogenesis and modulates metabolism via ROS-mediated signaling — a systemic effect beyond the gut.